Andrzej Schonert, CEO of Synoptis Industrial, discusses the intricacies of the Polish market and the requirement to move into niche areas, mainly in Rx, to concentrate their pharmaceutical offering to pharmacists, and in the future, hospitals. Furthermore, he highlights the company’s CMO activities and services to assist foreign players to enter Poland and the wider European market.
What have been the major milestones for the company over the last two years?
"A large percentage of the production cost is materials, and although Poland is not the cheapest, a huge focus of ours is to ensure high-quality."
